Supplementary Table 4 from AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
收藏数据链接：
官方服务：
资源简介：
KRAS mutation status of cell lines included in in vitro combination screen
创建时间：
2021-02-01
